glp 1 gip dual agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Review Article: GLP‐1 Receptor Agonists
Description
10.1038/s41413-024-00374-0 5 BrakenridgeS
Our current practice is to consider a ~20% bolus insulin decrease and a ~10% basal insulin decrease before GLP-1RA initiation, although prior A1c, risk of hypoglycemia, potential risk of ketosis due to reduced insulin doses, as well as other patient-specific factors should guide the final insulin dose changes
Glucagon-Like Peptide-1 Receptor Agonists During Pregnancy and Lactation
Among those on the highest dose, 54.6% achieved at least 10% weight loss, 36.0% achieved 15% or more, and 18.4% achieved 20% or more
